Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Efficacy, Safety and Tolerability of 0.05% Cyclosporine and 0.1% Tacrolimus Eye Drops in the Treatment of Chronic Ocular Graft-versus-host Disease

NCT05294666 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT05294666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05294666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Efficacy, Safety and Tolerability of 0.05% Cyclosporine and 0.1% Tacrolimus Eye Drops in the Treatment of Chronic Ocular Graft-versus-host Disease
Lead sponsor
Peking University Third Hospital
Phase
Phase 4
Overall status
Completed
Start date
April 1, 2020
Completion date
July 1, 2021
Enrollment
89 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease in eye